An 'Export-Only' Exception to Pharmaceutical Patents in Europe: Should the U.S. Follow Suit?

Nature Biotechnology, Vol. 37, No. 1, 03.01.2019, p. 21-22.

Posted: 24 Apr 2019

See all articles by Timo Minssen

Timo Minssen

University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law

Aaron S. Kesselheim

Brigham and Women's Hospital/Harvard Medical School

Jonathan J. Darrow

Harvard Medical School

Multiple version iconThere are 2 versions of this paper

Date Written: March 26, 2019

Abstract

A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.

Suggested Citation

Minssen, Timo and Kesselheim, Aaron S. and Darrow, Jonathan J., An 'Export-Only' Exception to Pharmaceutical Patents in Europe: Should the U.S. Follow Suit? (March 26, 2019). Nature Biotechnology, Vol. 37, No. 1, 03.01.2019, p. 21-22., Available at SSRN: https://ssrn.com/abstract=3360308

Timo Minssen (Contact Author)

University of Copenhagen - Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) - Faculty of Law ( email )

Karen Blixens Plads 16
Copenhagen, 2300
Denmark
+46 708 607517 (Phone)

HOME PAGE: http://jura.ku.dk/cebil/staff/profile/?pure=en/persons/381631

Aaron S. Kesselheim

Brigham and Women's Hospital/Harvard Medical School ( email )

1620 Tremont St
Suite 3030
Boston, MA 02120
United States
617-278-0930 (Phone)
617-232-8602 (Fax)

HOME PAGE: http://www.PORTALresearch.org

Jonathan J. Darrow

Harvard Medical School ( email )

25 Shattuck St
Boston, MA 02115
United States

Do you have negative results from your research you’d like to share?

Paper statistics

Abstract Views
376
PlumX Metrics